Glassman Wealth Services’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-68
Closed -$2.51K 875
2023
Q4
$2.51K Hold
68
﹤0.01% 1280
2023
Q3
$2.6K Hold
68
﹤0.01% 1252
2023
Q2
$2.45K Sell
68
-8
-11% -$273 ﹤0.01% 1181
2023
Q1
$2.9K Hold
76
﹤0.01% 1145
2022
Q4
$4.32K Hold
76
﹤0.01% 1061
2022
Q3
$3K Hold
76
﹤0.01% 1132
2022
Q2
$3K Hold
76
﹤0.01% 1141
2022
Q1
$3K Hold
76
﹤0.01% 1131
2021
Q4
$3K Buy
76
+50
+192% +$1.87K ﹤0.01% 1100
2021
Q3
$1K Hold
26
﹤0.01% 1362
2021
Q2
$1K Hold
26
﹤0.01% 1299
2021
Q1
$1K Buy
26
+3
+13% +$137 ﹤0.01% 1259
2020
Q4
$1K Hold
23
﹤0.01% 1217
2020
Q3
$1K Hold
23
﹤0.01% 1163
2020
Q2
$1K Buy
23
+5
+28% +$113 ﹤0.01% 1030
2020
Q1
$0 Hold
18
﹤0.01% 1302
2019
Q4
$0 Buy
+18
New +$312 ﹤0.01% 1299

Other funds holding HALO

Glassman Wealth Services's HALO Position: Q1 2024 in Review

Glassman Wealth Services sold out of Halozyme (HALO) in Q1 2024, closing a stake of 68 shares — an estimated $2.51K sold.

Glassman Wealth Services first reported a position in HALO in Q4 2019 and held it in 17 quarters. The position peaked at $4.32K in Q4 2022. 414 funds tracked by Wall St. Rank hold HALO as of Q1 2024.

  • Glassman Wealth Services reported no remaining Halozyme position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 68 Halozyme shares in Q1 2024, an estimated $2.51K.
  • Glassman Wealth Services first reported a position in Halozyme in Q4 2019 and held it in 17 quarters.
  • Glassman Wealth Services's Halozyme position peaked at $4.32K in Q4 2022.
  • 414 funds tracked by Wall St. Rank held Halozyme as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.